Canada-European Trade Agreement. Provide input into the Government of Canada's negotiations regarding the Canada-European Union Comprehensive Economic and Trade Agreement (CETA) with respect to pharmaceuticals, counterfeit medicines, border measures and intellectual property.
Legislative Proposal, Bill or Resolution, Policies or Program
The Bill formerly known as Bill C-393 (Canada Access to Medicines Regime) with respect to simplifying the process for pharmaceutical manufacturers to participate including sections on requirements, process, outcomes and responsibilities.
Legislative Proposal, Bill or Resolution, Regulation
Patent Act - lobby for changes on all rules and processes for the listing of generic pharmaceutical products.
Policies or Program, Regulation
Trade Agreements (NAFTA) North American Free Trade Agreement, WTO (World Trade Organization), European-Canada Free Trade Agreement policies, regulations,patents: with respect to terms, dispute settlements; pharmaceutical products policies, reviews/changes/updates; and all other changes that impact the ability to introduce products or export to other countries.
Health Canada generic submissions review/approvals: with respect to the submission of new generic products to Health Canada and the resources, timing, structures and requirements needed to complete process.
Notice of compliance regulations (NOC): with respect to application of regulations, reviews/changes as it relates to the approval of generic drugs in Canada.
Who is being lobbied?
Canadian Heritage (PCH)
Canadian International Trade Tribunal (CITT)
Competition Bureau Canada (COBU)
Competition Tribunal (CT)
Finance Canada (FIN)
Global Affairs Canada (GAC)
Health Canada (HC)
House of Commons
Innovation, Science and Economic Development Canada (ISED)